Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
暂无分享,去创建一个
A. Grada | Jodi L. Johnson | J. Keri | S. Tanaka | G. Damiani | C. Bunick | Nika Furey | Ayman Grada
[1] Gerard D. Wright,et al. The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents. , 2021, Chemical reviews.
[2] B. Alkhawaja,et al. Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: a cross sectional study , 2020, BMC Dermatology.
[3] A. Armstrong,et al. ARTICLE: Oral Tetracyclines and Acne: A Systematic Review for Dermatologists. , 2020, Journal of drugs in dermatology : JDD.
[4] R. Hazan,et al. Antibiotic Susceptibility of Cutibacterium acnes Strains Isolated from Israeli Acne Patients , 2020, Acta dermato-venereologica.
[5] A. Joshi,et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. , 2020, The lancet. Gastroenterology & hepatology.
[6] I. Lomakin,et al. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome , 2020, Proceedings of the National Academy of Sciences.
[7] A. Grada,et al. Sarecycline: A Review of Preclinical and Clinical Evidence , 2020, Clinical, cosmetic and investigational dermatology.
[8] I. Lomakin,et al. 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution , 2020, Journal of Investigative Dermatology.
[9] A. Grada,et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials , 2020 .
[10] C. Antonescu,et al. Minocycline and Its Impact on Microbial Dysbiosis in the Skin and Gastrointestinal Tract of Acne Patients , 2020, Annals of dermatology.
[11] D. Pariser,et al. Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study. , 2019, The Journal of clinical and aesthetic dermatology.
[12] D. Margolis,et al. Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016 , 2019, JAMA dermatology.
[13] G. Zhanel,et al. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris , 2018, Antimicrobial Agents and Chemotherapy.
[14] N. Sadick,et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. , 2018, Journal of drugs in dermatology : JDD.
[15] J. Leyden,et al. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. , 2018, Journal of Drugs in Dermatology.
[16] R. Ebright,et al. White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs , 2017, The Journal of infectious diseases.
[17] E. Tan,et al. The use of oral antibiotics in treating acne vulgaris: a new approach , 2016, Dermatologic therapy.
[18] S. Pradhan,et al. Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology , 2016, Indian journal of dermatology.
[19] C. Chukwudi. rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines , 2016, Antimicrobial Agents and Chemotherapy.
[20] T. Grossman. Tetracycline Antibiotics and Resistance. , 2016, Cold Spring Harbor perspectives in medicine.
[21] J. Leyden,et al. Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, , 2016, The Journal of clinical and aesthetic dermatology.
[22] M. P. Francino,et al. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances , 2016, Front. Microbiol..
[23] C. Tait,et al. Non‐antibiotic properties of tetracyclines and their clinical application in dermatology , 2014, The Australasian journal of dermatology.
[24] Daniel N. Wilson,et al. Tetracycline antibiotics and resistance mechanisms , 2014, Biological chemistry.
[25] P. Gibson,et al. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad , 2013, Internal medicine journal.
[26] K. Schulten,et al. Mechanism of Tetracycline Resistance by Ribosomal Protection Protein Tet(O) , 2013, Nature Communications.
[27] F. Abdi,et al. Staphylococcus aureus in Acne Pathogenesis: A Case-Control Study , 2012, North American journal of medical sciences.
[28] Stephan Wickles,et al. Structural basis for TetM-mediated tetracycline resistance , 2012, Proceedings of the National Academy of Sciences.
[29] Y. Wiener-Well,et al. Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection , 2012, Antimicrobial Agents and Chemotherapy.
[30] Rachel A. Gordon,et al. New antibiotic therapies for acne and rosacea , 2012, Dermatologic therapy.
[31] D. Margolis,et al. Antibiotics, acne, and Staphylococcus aureus colonization. , 2011, Archives of dermatology.
[32] F. Villarreal,et al. Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action , 2010, Pharmacological Research.
[33] David J Margolis,et al. Potential Association Between the Oral Tetracycline Class of Antimicrobials Used to Treat Acne and Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[34] L. Kircik. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. , 2010, Journal of drugs in dermatology : JDD.
[35] M. M. Coelho,et al. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. , 2007, European journal of pharmacology.
[36] G. Webster,et al. Anti-inflammatory activity of tetracyclines. , 2007, Dermatologic clinics.
[37] P. Chabrier,et al. Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline. , 2004, European journal of pharmacology.
[38] W. Cunliffe,et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar , 2004, The British journal of dermatology.
[39] Marilyn Roberts,et al. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.
[40] S. B. Singer,et al. Pediatric tetracycline-induced pseudotumor cerbri. , 1999, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[41] A. Spinillo,et al. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. , 1999, American journal of obstetrics and gynecology.
[42] W. Cunliffe,et al. Safety of long‐term high‐dose minocycline in the treatment of acne , 1996, The British journal of dermatology.
[43] M. Pato. Tetracycline Inhibits Propagation of Deoxyribonucleic Acid Replication and Alters Membrane Properties , 1977, Antimicrobial Agents and Chemotherapy.
[44] M. Barza,et al. Relation Between Lipophilicity and Pharmacological Behavior of Minocycline, Doxycycline, Tetracycline, and Oxytetracycline in Dogs , 1975, Antimicrobial Agents and Chemotherapy.
[45] J. Bartlett,et al. Comparative Effect of Tetracycline and Doxycycline on the Occurrence of Resistant Escherichia coli in the Fecal Flora , 1975, Antimicrobial Agents and Chemotherapy.